$GOSS
Gossamer Bio, Inc. Stock $goss

$goss Overview Financials Valuation SEC Filings Company Website

2022 Q2 Form 10-Q Financial Statement

#000172811722000047 Filed on May 10, 2022

Income Statement

Concept	2022 Q2	2022 Q1	2021 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$11.28M	$12.00M	$10.71M
YoY Change	0.12%	5.74%	-32.53%
% of Gross Profit
Research & Development	$42.58M	$42.32M	$40.93M
YoY Change	-3.92%	1.18%	5.2%
% of Gross Profit
Depreciation & Amortization	$460.0K	$500.0K	$448.0K
YoY Change	9.0%	25.0%	21.08%
% of Gross Profit
Operating Expenses	$53.86M	$54.34M	$51.65M
YoY Change	-3.13%	2.14%	-5.74%
Operating Profit	-$53.87M	-$54.34M
YoY Change	-3.1%	2.14%
Interest Expense	-$3.181M	$3.467M	-$4.701M
YoY Change	-165.8%	-27.47%	34.31%
% of Operating Profit
Other Income/Expense, Net	$587.0K	-$3.442M	$78.00K
YoY Change	-113.86%	-22.44%	-107.65%
Pretax Income	-$56.47M	-$57.79M	-$56.28M
YoY Change	-5.63%	0.25%	-12.87%
Income Tax
% Of Pretax Income
Net Earnings	-$56.47M	-$57.79M	-$56.28M
YoY Change	-5.63%	0.25%	-12.87%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.74	-$0.76
Diluted Earnings Per Share	-$736.5K	-$0.76	-$744.5K
COMMON SHARES
Basic Shares Outstanding	77.12M shares	75.89M shares	76.46M shares
Diluted Shares Outstanding	76.67M shares	75.89M shares

Balance Sheet

Concept	2022 Q2	2022 Q1	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$222.2M	$271.6M	$325.2M
YoY Change	-45.27%	-40.08%	-36.56%
Cash & Equivalents	$94.32M	$138.9M	$183.4M
Short-Term Investments	$127.8M	$132.7M	$141.8M
Other Short-Term Assets	$10.52M	$9.151M	$6.562M
YoY Change	-4.94%	-27.37%	-32.35%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$232.7M	$280.8M	$331.8M
YoY Change	-44.2%	-39.73%	-36.48%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.91M	$5.025M	$5.320M
YoY Change	111.43%	-15.12%	-3.87%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.254M	$1.019M	$1.080M
YoY Change	17.2%	0.89%	5.16%
Total Long-Term Assets	$13.16M	$13.91M	$11.88M
YoY Change	-15.21%	-16.35%	-30.59%
TOTAL ASSETS
Total Short-Term Assets	$232.7M	$280.8M	$331.8M
Total Long-Term Assets	$13.16M	$13.91M	$11.88M
Total Assets	$245.8M	$294.7M	$343.7M
YoY Change	-43.16%	-38.92%	-36.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.908M	$592.0K	$3.244M
YoY Change	336.65%	-44.83%	-56.79%
Accrued Expenses	$28.89M	$17.02M	$20.41M
YoY Change	81.9%	0.93%	-1.45%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$11.61M	$0.00	$0.00
YoY Change
Total Short-Term Liabilities	$44.41M	$34.57M	$39.86M
YoY Change	48.12%	17.4%	3.13%
LONG-TERM LIABILITIES
Long-Term Debt	$212.9M	$29.17M	$29.08M
YoY Change	636.66%	1.19%	1.17%
Other Long-Term Liabilities	$4.966M	$5.706M	$3.218M
YoY Change	-19.45%	-18.49%	-58.21%
Total Long-Term Liabilities	$217.9M	$29.17M	$29.08M
YoY Change	653.84%	1.19%	1.17%
TOTAL LIABILITIES
Total Short-Term Liabilities	$44.41M	$34.57M	$39.86M
Total Long-Term Liabilities	$217.9M	$29.17M	$29.08M
Total Liabilities	$262.3M	$264.5M	$222.2M
YoY Change	23.84%	25.73%	1.57%
SHAREHOLDERS EQUITY
Retained Earnings		-$860.6M	-$811.5M
YoY Change		35.48%	40.53%
Common Stock		$891.1M	$933.0M
YoY Change		-1.76%	3.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$16.46M	$30.16M	$121.5M
YoY Change
Total Liabilities & Shareholders Equity	$245.8M	$294.7M	$343.7M
YoY Change	-43.16%	-38.92%	-36.29%

Cashflow Statement

Concept	2022 Q2	2022 Q1	2021 Q4
OPERATING ACTIVITIES
Net Income	-$56.47M	-$57.79M	-$56.28M
YoY Change	-5.63%	0.25%	-12.87%
Depreciation, Depletion And Amortization	$460.0K	$500.0K	$448.0K
YoY Change	9.0%	25.0%	21.08%
Cash From Operating Activities	-$48.82M	-$53.48M	-$40.51M
YoY Change	2.9%	-9.19%	10.26%
INVESTING ACTIVITIES
Capital Expenditures	-$120.0K	$157.0K	-$83.00K
YoY Change	-14.29%	-80.42%	-66.8%
Acquisitions
YoY Change
Other Investing Activities	$4.799M	$8.577M	$10.53M
YoY Change	-109.61%	-32.83%	-82.84%
Cash From Investing Activities	$4.679M	$8.420M	$10.44M
YoY Change	-109.34%	-29.65%	-82.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$0.00
YoY Change
Cash From Financing Activities	21.00K	$721.0K	371.0K
YoY Change	-92.36%	-6.85%	48.4%
NET CHANGE
Cash From Operating Activities	-48.82M	-$53.48M	-40.51M
Cash From Investing Activities	4.679M	$8.420M	10.44M
Cash From Financing Activities	21.00K	$721.0K	371.0K
Net Change In Cash	-44.12M	-$44.50M	-29.69M
YoY Change	-54.63%	-4.1%	-220.66%
FREE CASH FLOW
Cash From Operating Activities	-$48.82M	-$53.48M	-$40.51M
Capital Expenditures	-$120.0K	$157.0K	-$83.00K
Free Cash Flow	-$48.70M	-$53.64M	-$40.43M
YoY Change	2.95%	-10.15%	10.79%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001728117
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate202006Member
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-38796
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	GOSSAMER BIO, INC.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-5461709
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	3013 Science Park Road
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
CY2022Q1	dei	City Area Code CityAreaCode	858
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	684-1300
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2022Q1	dei	Trading Symbol TradingSymbol	GOSS
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	77116705	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	138907000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	183403000	USD
CY2022Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	132716000	USD
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	141815000	USD
CY2022Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	64000	USD
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	64000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9087000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6498000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	280774000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	331780000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5025000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5320000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7861000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5477000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1019000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1080000	USD
CY2022Q1	us-gaap	Assets Assets	294679000	USD
CY2021Q4	us-gaap	Assets Assets	343657000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	592000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3244000	USD
CY2022Q1	goss	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	16958000	USD
CY2021Q4	goss	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	16205000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17018000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	20410000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	34568000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	39859000	USD
CY2022Q1	goss	Long Term Convertible Senior Notes LongTermConvertibleSeniorNotes	195079000	USD
CY2021Q4	goss	Long Term Convertible Senior Notes LongTermConvertibleSeniorNotes	150038000	USD
CY2022Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	29167000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	29079000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5706000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3218000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	264520000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	222194000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	700000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	700000000	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	77106185	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	76553937	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	76470588	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	75752664	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	8000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	8000	USD
CY2022Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	891121000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	932944000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-860630000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-811534000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-340000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	45000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	30159000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	121463000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	294679000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	343657000	USD
CY2022Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	42322000	USD
CY2021Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	41827000	USD
CY2022Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	20000	USD
CY2021Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	30000	USD
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12001000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11346000	USD
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	54343000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	53203000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-54343000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-53203000	USD
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	224000	USD
CY2021Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	193000	USD
CY2022Q1	us-gaap	Interest Expense InterestExpense	3467000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	4780000	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-199000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	149000	USD
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3442000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4438000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-57785000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-57641000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-8000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-372000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-377000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-69000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-385000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-441000	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-58170000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-58082000	USD
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.76
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.76
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.78
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.78
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	75894692	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	75894692	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74093526	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74093526	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	121463000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	126000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10983000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	595000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-57785000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-385000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	30159000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	320684000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	15000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8708000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	759000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-57641000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-441000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	272084000	USD
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-57785000	USD
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-57641000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	452000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	416000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	10983000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	8708000	USD
CY2022Q1	goss	In Process Research And Development Expenses InProcessResearchAndDevelopmentExpenses	20000	USD
CY2021Q1	goss	In Process Research And Development Expenses InProcessResearchAndDevelopmentExpenses	30000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	645000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	858000	USD
CY2022Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	292000	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1605000	USD
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-125000	USD
CY2021Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-66000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2589000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2855000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-61000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-16000	USD
CY2022Q1	goss	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	683000	USD
CY2021Q1	goss	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-117000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2507000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-6565000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	52000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-729000	USD
CY2022Q1	goss	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	753000	USD
CY2021Q1	goss	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	1078000	USD
CY2022Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-5802000	USD
CY2021Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-6500000	USD
CY2022Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	2500000	USD
CY2021Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	2500000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-53483000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-58896000	USD
CY2022Q1	goss	Payments For Proceeds From Research And Development Asset Acquisitions PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions	20000	USD
CY2021Q1	goss	Payments For Proceeds From Research And Development Asset Acquisitions PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions	30000	USD
CY2022Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	37403000	USD
CY2021Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
CY2022Q1	goss	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	46000000	USD
CY2021Q1	goss	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	12800000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	157000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	802000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	8420000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	11968000	USD
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	126000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	15000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	721000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	774000	USD
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-154000	USD
CY2021Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-242000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-44496000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-46396000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	183467000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	486620000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	138971000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	439982000	USD
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	675000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	675000	USD
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3029000	USD
CY2021Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2022Q1	goss	Noncash Investing And Financing Activities Change In Unrealized Gain On Marketable Securities Net Of Tax NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax	-377000	USD
CY2021Q1	goss	Noncash Investing And Financing Activities Change In Unrealized Gain On Marketable Securities Net Of Tax NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax	-69000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-860600000	USD
	goss	Funds Raised Through Preferred Equity Financing Convertible Note Financings And Completed Initial Public Offering FundsRaisedThroughPreferredEquityFinancingConvertibleNoteFinancingsAndCompletedInitialPublicOffering	942000000	USD
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s condensed consolidated financial statements relate to the allocation of the 2027 Notes into liability and equity components and accrued research and development expenses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div>
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	28058796	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	27723320	shares
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9756000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9600000	USD
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4731000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4280000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5025000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5320000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	500000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	400000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6114000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11916000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2761000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2902000	USD
CY2022Q1	goss	Accrued Consulting Fees Current AccruedConsultingFeesCurrent	956000	USD
CY2021Q4	goss	Accrued Consulting Fees Current AccruedConsultingFeesCurrent	956000	USD
CY2022Q1	us-gaap	Interest Payable Current InterestPayableCurrent	3566000	USD
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1066000	USD
CY2022Q1	goss	Accrued Legal Fees Current AccruedLegalFeesCurrent	320000	USD
CY2021Q4	goss	Accrued Legal Fees Current AccruedLegalFeesCurrent	202000	USD
CY2022Q1	us-gaap	Litigation Reserve Current LitigationReserveCurrent	2375000	USD
CY2021Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	2375000	USD
CY2022Q1	goss	Accrued Accounting Fees Current AccruedAccountingFeesCurrent	232000	USD
CY2021Q4	goss	Accrued Accounting Fees Current AccruedAccountingFeesCurrent	154000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	694000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	839000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17018000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	20410000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	133142000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	426000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	132716000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	141863000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	48000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	141815000	USD
CY2022Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	19000000	USD
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	10000000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Maturities Remainder Of Fiscal Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue	132716000	USD
CY2022Q1	goss	Available For Sale Securities Debt Maturities After One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearFairValue	0	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	132716000	USD
CY2018Q2	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	20000000	USD
CY2022Q1	goss	Common Stock Voting Rights Number Of Votes Per Share CommonStockVotingRightsNumberOfVotesPerShare	1	vote
CY2022Q1	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares	552251	shares
CY2021Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares	717927	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9434660	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.24
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M24D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	15822000000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4041165	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	11.86
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	39525	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.18
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	114608	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	15.49
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13321692	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.13
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M24D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	7047000000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	13321692	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	12.13
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y10M24D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	7047000000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	5549308	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	12.40
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y6M
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	6670000000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	9.27
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10983000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8708000	USD
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.07
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	761000	USD
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1038000	USD
CY2022Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	10000	USD
CY2021Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	9000	USD
CY2022Q1	us-gaap	Lease Cost LeaseCost	771000	USD
CY2021Q1	us-gaap	Lease Cost LeaseCost	1047000	USD
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	800000	USD
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1100000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2421000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3319000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3419000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	144000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	9303000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	836000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	8467000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2761000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5706000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	8467000	USD
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	900000	USD
CY2021Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	1000000	USD
CY2021Q4	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-2400000	USD
CY2021Q4	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-2400000	USD

Files In Submission

Name	View Source	Status
0001728117-22-000047-index-headers.html	Edgar Link	pending
0001728117-22-000047-index.html	Edgar Link	pending
0001728117-22-000047.txt	Edgar Link	pending
0001728117-22-000047-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
goss-20220331.htm	Edgar Link	pending
goss-20220331.xsd	Edgar Link	pending
goss-20220331x10qxexx311.htm	Edgar Link	pending
goss-20220331x10qxexx312.htm	Edgar Link	pending
goss-20220331x10qxexx321.htm	Edgar Link	pending
goss-20220331x10qxexx322.htm	Edgar Link	pending
goss-20220331_cal.xml	Edgar Link	unprocessable
goss-20220331_def.xml	Edgar Link	unprocessable
goss-20220331_htm.xml	Edgar Link	completed
goss-20220331_lab.xml	Edgar Link	unprocessable
goss-20220331_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GOSS
Gossamer Bio, Inc. Stock $goss

2022 Q2 Form 10-Q Financial Statement

#000172811722000047 Filed on May 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GOSS Gossamer Bio, Inc. Stock $goss

2022 Q2 Form 10-Q Financial Statement

#000172811722000047 Filed on May 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GOSS
Gossamer Bio, Inc. Stock $goss